<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747472</url>
  </required_header>
  <id_info>
    <org_study_id>UHG-CFD-GIPANTA-1</org_study_id>
    <nct_id>NCT02747472</nct_id>
  </id_info>
  <brief_title>GIP Receptor Antagonist Studies in Humans</brief_title>
  <acronym>GA-1</acronym>
  <official_title>Involvement of Glucose-dependent Insulinotropic Polypeptide (GIP) in Human Physiology and Pathophysiology - Receptor Antagonist Studies in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of
      insulin secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To evaluate the GIP receptor antagonizing effect of peptide-based competitive GIP
      receptor antagonist GIP-A (vs. saline (placebo)) in 10 healthy subjects during 1 hour
      hyperglycaemic clamps with and without concomitant iv infusion of GIP[1-42]. The intention is
      to establish GIP-A as a tool to eliminate glucose-dependent insulinotropic GIP signalling.

      The study consists of four experimental days (A-D) with assessment of beta cell function
      during 12 mM-hyperglycaemic clamps with concomitant infusions of A) GIP[1-42], B) GIP-A, C)
      GIP[1-42] + GIP-A, or D) saline (placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>65 minutes</time_frame>
    <description>Serum-insulin AUC (area under the curve for hyperglycemic clamp period)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Glucose Metabolism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP(1-42)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of agonist, GIP(1-42)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of GIP-A alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP-A + GIP(1-42)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of GIP-A and GIP(1-42)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIP-A</intervention_name>
    <description>GIP receptor antagonist</description>
    <arm_group_label>GIP-A</arm_group_label>
    <arm_group_label>GIP-A + GIP(1-42)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIP(1-42)</intervention_name>
    <description>GIP receptor agonist</description>
    <arm_group_label>GIP(1-42)</arm_group_label>
    <arm_group_label>GIP-A + GIP(1-42)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal kidney function, liver function and hemoglobin levels.

        Exclusion Criteria:

          -  Medication, Diabetes type 1 or 2, BMI &gt; 25, first degree relatives with Type 2
             Diabetes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UHGentofte, Center for Diabetes Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Diabetes Research</name>
      <address>
        <city>Copenhagen</city>
        <state>Gentofte</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>LÃ¦rke Smidt Gasbjerg</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>GIP</keyword>
  <keyword>GIP receptor antagonist</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

